Company: IXHL
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001213900-25-092837
Chunk: 113

Company: Incannex Healthcare Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 113
---
.

37

Inflation
and Seasonality

Management
believes inflation has not had a material impact on our operations or financial condition. Management further believes that our operations
are not currently subject to seasonal influences due to our current lack of marketed products. Moreover, the targets of our drug candidates
are not seasonal diseases. Accordingly, should any of our drug candidates be approved, management does not expect that our business would
be subject to seasonal influences.

Manufacturing
and Raw Materials

We have no manufacturing capabilities and, as noted above, are dependent
on third parties for the cost effective manufacture and manufacturing process development of our drug candidates. Problems with third-party
manufacturers or the manufacturing process as such may delay or jeopardize clinical trials and commercialization of our drug candidates.
We or our third-party manufacturers may also experience delays due to the DEA’s limitations on controlled substances discussed above.

Human
Capital Resources

As of June 30, 2025, we had a total of twelve employees, all of which
are full time. Of these employees, eight were employed in R&D and four were employed in general management and administration.

Each
of our full-time employees has entered into an employment agreement with an unlimited term. We may only terminate the employment of any
of our employees in accordance with the relevant employee contract of employment.

Our
standard contract of employment for full-time employees provides that we can terminate the employment of an employee without notice for
serious misconduct or with between one to six months’ notice without cause (as set out in the relevant employee’s contract
of employment).

38

Information About Our Directors and Executive
Officers

The following persons currently serve as our directors
and executive officers:

    Directors and Executive Officers
     
    Position
  
    Executive Officers

    Joel Latham
     
    President, Chief Executive Officer and Director
  
    Joseph Swan
     
    Chief Financial Officer and Corporate Secretary
  
    Lou Barbato, M.D.
     
    Chief Medical Officer
  
    Lekhram Changoer
     
    Chief Technology Officer
  
    Directors

    Troy Valentine
     
    Director/Co-Founder, Alignment Capital Pty Ltd
  
    Peter Widdows

    Board Chair and Non-Executive Director, Youi Insurance

Non-Executive Chaiman, Sunny Queens Australia

    George Anastassov, M.D.
     
    Doctor, Maxillofacial Surgery Services
  
    Robert Clark
     
    Vice President, Regulatory Affairs, Novo Nordisk A